

Clinigen Pharma Limited

Report and Unaudited Financial Statement

Year Ended

30 June 2014

Company Number 07248508

TUESDAY



A44D06MQ

A08

31/03/2015

#43

COMPANIES HOUSE

Clinigen Pharma Limited

Report and financial statement
for the year ended 30 June 2014

Contents

Page:

1	Report of the directors
2	Profit and loss account
2	Balance sheet
3	Notes forming part of the financial statement

Directors

P L George
R A Sibson
S Chilton

Secretary and registered office

R A Sibson, Pitcairn House, Crown Square, First Avenue, Burton-On-Trent, Staffordshire, DE14 2WW

Company number

07248508

Clinigen Pharma Limited

Report of the directors for the year ended 30 June 2014

The directors present their report together with the financial statement for the year ended 30 June 2014.

Statement of director's responsibilities

The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period in preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable him to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities

Principal activities

The company has not traded during the year and remains dormant. The directors have prepared this report in accordance with the special provisions relating to small companies within Part 16 of the Companies Act 2006. The company was entitled to exemption from audit under Section 480 of the Companies Act 2006. The directors have taken advantage of the small companies' exemption in Section 172 of the Companies Act 2006 and not prepared a Strategic Report for the financial year.

Directors

The directors who served during the year were:

R A Sibson
P L George
S E Chilton (appointed 1 April 2014)

In preparing this directors' report advantage has been taken of the small companies' exemption.

By order of the Board



S E Chilton
Director

Date 30 March 2015

Clinigen Pharma Limited

Profit and loss account For the year ended 30 June 2014

The company has not traded during the year or the preceding financial year. During these periods, the company received no income and incurred no expenditure and therefore made neither profit or loss.

Balance sheet at 30 June 2014

Company number 07248508	Note	2014 £	2013 £
Current assets			
Debtors	3	10,000	10,000
		<u> </u>	<u> </u>
Capital and reserves			
Called up share capital	4	10,000	10,000
		<u> </u>	<u> </u>
Shareholders' funds		<u>10,000</u>	<u>10,000</u>

The company did not trade during the current or preceding year and, accordingly, no profit and loss account has been prepared. The company has not received any income or incurred any expense or recognised any other gains or losses during the current or preceding year.

For the year ended 30 June 2014, the company was entitled to exemption from audit under section 480 of the Companies Act 2006 ("the Act") relating to dormant companies.

The members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statement was approved by the Board of Directors and authorised for issue on 30 March 2015



S E Chilton
Director

The notes on page 3 form part of these financial statements.

Clinigen Pharma Limited

Notes forming part of the financial statements for the year ended 30 June 2014

1 Accounting policies

Basis of preparation of financial statements

The financial statements have been prepared in accordance with applicable accounting under the historical cost convention.

2 Profit

During the year, no director received any emoluments (2013 - £Nil).

3 Debtors

	2014 £	2013 £
Other debtors	10,000	10,000

4 Share capital

	2014 £	2013 £
Issued, allotted, called up and fully paid		
760 ordinary shares of £10 each	7,600	7,600
240 'A' Ordinary shares of £10 each	2,400	2,400
	<u>10,000</u>	<u>10,000</u>

5 Ultimate parent undertaking and controlling party

The ultimate parent undertaking is Clinigen Group plc, a company incorporated in England and Wales. This is the only company in the Group that prepare consolidated financial statements. These are available to the public and may be obtained from Clinigen Group plc's Head Office at Pitcairn House, Crown Square, First Avenue, Burton-On-Trent, Staffordshire, DE14 2WW.